News Releases

scPharmaceuticals Inc. Reports Third Quarter 2018 Financial Results and Provides Business Update
Resubmission of FURSOCIX® with the U.S. Food and Drug Administration ( FDA ) by year-end 2019 Balance sheet remains strong with over $95 million in cash BURLINGTON, Mass. , Nov. 13, 2018 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and[…]
scPharmaceuticals Inc. Provides Regulatory Update on FUROSCIX®
Type A Post-Action Meeting Minutes Received BURLINGTON, Mass. , Oct. 18, 2018 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient[…]
scPharmaceuticals Inc. Reports Second Quarter 2018 Financial Results and Provides Business Update
Request for Type A meeting was granted by the U.S. Food and Drug Administration to discuss the Complete Response Letter received in June 2018 Balance sheet remains strong with over $100 million in cash BURLINGTON, Mass. , Aug. 14, 2018 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc.[…]
scPharmaceuticals Announces Appointment of Two New Directors
BURLINGTON, Mass. , July 24, 2018 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs, announced[…]
scPharmaceuticals Appoints Frederick Hudson to Board of Directors
BURLINGTON, Mass. , June 28, 2018 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs, announced[…]
scPharmaceuticals Receives Complete Response Letter from the FDA for FUROSCIX®

BURLINGTON, Mass. , June 13, 2018 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs, today

[…]
scPharmaceuticals Inc. Provides Regulatory Update on FUROSCIX®

BURLINGTON, Mass. , May 31, 2018 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs, today

[…]
scPharmaceuticals Inc. to Present at the Jefferies 2018 Global Healthcare Conference

BURLINGTON, Mass. , May 30, 2018 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to optimize the delivery of infused therapies, advance patient care and reduce healthcare costs, today

[…]
scPharmaceuticals Inc. Reports First Quarter 2018 Financial Results and Provides Business Update
Company’s lead investigational product, FUROSCIX ® , has a PDUFA date of June 23, 2018 Company has initiated staged commercialization activities for FUROSCIX BURLINGTON, Mass. , May 07, 2018 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq:SCPH), a pharmaceutical company focused on developing and[…]
scPharmaceuticals Inc. Reports Fourth Quarter 2017 Financial Results
Announced $147.7 Million of equity capital raising in 2017;  Completed an Initial Public Offering;  Advances towards FUROSCIX™ PDUFA date BURLINGTON, Mass. , March 20, 2018 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq: SCPH), a pharmaceutical company focused on developing and commercializing[…]
scPharmaceuticals Inc. to Present at the Cowen 38th Annual Health Care Conference
BURLINGTON, Mass. , March 01, 2018 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to transform infused therapies, advance patient care and reduce healthcare costs, today announced that[…]
scPharmaceuticals Inc. to Present at the 7th Annual Leerink Partners Global Healthcare Conference
BURLINGTON, Mass. , Feb. 06, 2018 (GLOBE NEWSWIRE) -- scPharmaceuticals Inc. (Nasdaq:SCPH), a pharmaceutical company focused on developing and commercializing products that have the potential to transform infused therapies, advance patient care and reduce healthcare costs, today announced that John[…]